A charting tool for estimating the PSA doubling time in patients with prostate cancer.
暂无分享，去创建一个
[1] J. Hanley,et al. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. , 2004, Journal of Urology.
[2] A. Renshaw,et al. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. , 2003, The Journal of urology.
[3] Ming-Hui Chen,et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.
[4] L. Bégin,et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. , 2002, Urology.
[5] A. Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[6] G. Duncan,et al. Watchful waiting or watchful progression? , 1998, Cancer.
[7] J. Dekernion,et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.
[8] H M Sandler,et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. , 1997, International journal of radiation oncology, biology, physics.